Nanotherapeutics in the EU: an overview on current state and future directions

References

• MurthySKNanoparticles in modern medicine: state of the art and future challengesInt J Nanomedicine20072212914117722542
   PubMed Web of Science ®Google Scholar
• MuraSCouvreurPNanotheranostics for personalized medicineAdv Drug Deliv Rev201264131394141622728642
   PubMed Web of Science ®Google Scholar
• RizzoLYTheekBStormGKiesslingFLammersTRecent progress in nanomedicine: therapeutic, diagnostic and theranostic applicationsCurr Opin Biotechnol20132461159116623578464
   PubMed Web of Science ®Google Scholar
• WagnerWHuüsingBGaisserSBockANanomedicine: drivers for development and possible impactsCentre ECJR, Studies IfPT, trans: European Commission Joint Research Centre, Institute for Prospective Technological Studies2006
   Google Scholar
• WebsterTJProjections for nanomedicine into the next decade: but is it all about pharmaceuticals?Int J Nanomedicine200831i
   Web of Science ®Google Scholar
• HuberFXMcArthurNHeimannLEvaluation of a novel nanocrystalline hydroxyapatite paste Ostim in comparison to Alpha-BSM - more bone ingrowth inside the implanted material with Ostim compared to Alpha BSMBMC Musculoskelet Disord20091016420028538
   PubMed Web of Science ®Google Scholar
• PepićIHafnerALovrićJPirkićBFilipović-GrčićJA nonionic surfactant/chitosan micelle system in an innovative eye drop formulationJ Pharm Sci201099104317432520310026
   PubMed Web of Science ®Google Scholar
• JunghannsJUMuüllerRHNanocrystal technology, drug delivery and clinical applicationsInt J Nanomedicine20083329530918990939
   PubMed Web of Science ®Google Scholar
• ZhangXXEdenHSChenXPeptides in cancer nanomedicine: drug carriers, targeting ligands and protease substratesJ Control Release2012159121322056916
   PubMed Web of Science ®Google Scholar
• CrielaardBJLammersTSchiffelersRMStormGDrug targeting systems for inflammatory disease: one for all, all for oneJ Control Release2012161222523422226771
   PubMed Web of Science ®Google Scholar
• HafnerALovrićJVoinovichDFilipović-GrčićJMelatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayersInt J Pharm2009381220521319596430
   PubMed Web of Science ®Google Scholar
• PavelićZŠkalko-BasnetNFilipović-GrčićJMartinacAJalšenjakIDevelopment and in vitro evaluation of a liposomal vaginal delivery system for acyclovirJ Control Release20051061–2344315979189
   PubMed Web of Science ®Google Scholar
• PepićILovrićJFilipović-GrčićJHow do polymeric micelles cross epithelial barriers?Eur J Pharm Sci2013501425523619286
   PubMed Web of Science ®Google Scholar
• HafnerALovrićJPepićIFilipović-GrčićJLecithin/chitosan nanoparticles for transdermal delivery of melatoninJ Microencapsul201128880781522117177
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGDrug targeting to tumors: principles, pitfalls and (pre-) clinical progressJ Control Release2012161217518721945285
   PubMed Web of Science ®Google Scholar
• PetrosRADeSimoneJMStrategies in the design of nanoparticles for therapeutic applicationsNat Rev Drug Discov20109861562720616808
   PubMed Web of Science ®Google Scholar
• DuncanRGasparRNanomedicine(s) under the microscopeMol Pharm2011862101214121974749
   PubMed Web of Science ®Google Scholar
• Filipović-GrčićJMrharAJungingerHThematic Issue on Emerging nanopharmaceuticals for nonparenteral application routesEur J Pharm Sci2013501123747658
   PubMed Web of Science ®Google Scholar
• European Commission/ETP NanomedicineRoadmaps in Nanomedicine Towards 2020: Joint European Commission/ETP Nanomedicine expert reportEuropean Commission/ETP Nanomedicine2009 Available from: http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/091022_ETPN_Report_2009.pdfAccessed December 17, 2013
   Google Scholar
• SvensonSClinical translation of nanomedicinesCurr Opin Solid State Mater Sci2012166287294
   Web of Science ®Google Scholar
• BarenholzYDoxil®-the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• JabirNRTabrezSAshrafGMShakilSDamanhouriGAKamalMANanotechnology-based approaches in anticancer researchInt J Nanomedicine201274391440822927757
   PubMed Web of Science ®Google Scholar
• ChangHIYehMKClinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyInt J Nanomedicine20127496022275822
   PubMed Web of Science ®Google Scholar
• TorchilinVPRecent advances with liposomes as pharmaceutical carriersNat Rev Drug Discov20054214516015688077
   PubMed Web of Science ®Google Scholar
• DavisMEChenZGShinDMNanoparticle therapeutics: an emerging treatment modality for cancerNat Rev Drug Discov20087977178218758474
   PubMed Web of Science ®Google Scholar
• HofheinzRDGnad-VogtSUBeyerUHochhausALiposomal encapsulated anti-cancer drugsAnticancer Drugs200516769170716027517
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer200397112869287912767102
   PubMed Web of Science ®Google Scholar
• RahmanAMYusufSWEwerMSAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulationInt J Nanomedicine20072456758318203425
   PubMed Web of Science ®Google Scholar
• FukuiHKoikeTNakagawaTComparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulationsInt J Pharm20032671–210111214602388
   PubMedGoogle Scholar
• HamillRJAmphotericin B formulations: a comparative review of efficacy and toxicityDrugs201373991993423729001
   PubMed Web of Science ®Google Scholar
• AngstMSDroverDRPharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technologyClin Pharmacokinet200645121153117617112293
   PubMed Web of Science ®Google Scholar
• SeniorJHMedical applications of multivesicular lipid-based particles: DepoFoam™ encapsulated drugsLasicDDPapahadjopoulosDMedical Applications of LiposomesAmsterdam, The NetherlandsElsevier1998733750
   Google Scholar
• FramptonJEMifamurtide: a review of its use in the treatment of osteosarcomaPaediatr Drugs201012314115320481644
   PubMedGoogle Scholar
• ChenHKhemtongCYangXChangXGaoJNanonization strategies for poorly water-soluble drugsDrug Discov Today2011167–835436020206289
   PubMed Web of Science ®Google Scholar
• KeckCMMuüllerRHDrug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEur J Pharm Biopharm200662131616129588
   PubMed Web of Science ®Google Scholar
• XiaDCuiFPiaoHEffect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in ratsPharm Res20102791965197620585842
   PubMed Web of Science ®Google Scholar
• DesaiPRDateAAPatravaleVBOvercoming poor oral bioavailability using nanoparticle formulations – opportunities and limitationsDrug Discov Today Technol201292e87e95
   Google Scholar
• LuYParkKPolymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugsInt J Pharm201345319821422944304
   PubMed Web of Science ®Google Scholar
• TziomalosKAthyrosVGFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewInt J Nanomedicine20061212914717722529
   PubMed Web of Science ®Google Scholar
• FlorenceATAttwoodDPhysicochemical Principles of PharmacyFourth editionPharmaceutical PressLondon, UK200622
   Google Scholar
• BawaRNanoparticle-based therapeutics in humans: a surveyNanotechnol Law Bus200852137155
   Google Scholar
• ShegokarRMuüllerRHNanocrystals: industrially feasible multifunctional formulation technology for poorly soluble activesInt J Pharm20103991–212913920674732
   PubMed Web of Science ®Google Scholar
• BroughCWilliamsRO3rdAmorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug deliveryInt J Pharm2013453115716623751341
   PubMed Web of Science ®Google Scholar
• LingHLuomaJTHillemanDA review of currently available fenofibrate and fenofibric acid formulationsCardiol Res2013424755
   PubMedGoogle Scholar
• YooJWIrvineDJDischerDEMitragotriSBio-inspired, bioengineered and biomimetic drug delivery carriersNat Rev Drug Discov201110752153521720407
   PubMed Web of Science ®Google Scholar
• UsonisVBakasenasVValentelisRKatilieneGVidzenieneDHerzogCAntibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal)Vaccine200321314588459214575771
   PubMed Web of Science ®Google Scholar
• BovierPAEpaxal: a virosomal vaccine to prevent hepatitis A infectionExpert Rev Vaccines2008781141115018844588
   PubMed Web of Science ®Google Scholar
• HerzogCHartmannKKunziVEleven years of Inflexal V-a virosomal adjuvanted influenza vaccineVaccine200927334381438719450630
   PubMed Web of Science ®Google Scholar
• DuncanRPolymer therapeutics as nanomedicines: new perspectivesCurr Opin Biotechnol201122449250121676609
   PubMed Web of Science ®Google Scholar
• GasparRDuncanRPolymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeuticsAdv Drug Deliv Rev200961131220123119682513
   PubMed Web of Science ®Google Scholar
• PoelstraKPrakashJBeljaarsLDrug targeting to the diseased liverJ Control Release2012161218819722370583
   PubMed Web of Science ®Google Scholar
• DracaNLazicRSimicPDumic-CuleILueticATGabricNPotential beneficial role of sevelamer hydrochloride in diabetic retinopathyMed Hypotheses201380443143523357670
   PubMed Web of Science ®Google Scholar
• NarangASDelmarreDGaoDStable drug encapsulation in micelles and microemulsionsInt J Pharm20073451–292517945446
   PubMed Web of Science ®Google Scholar
• LawrenceMJReesGDMicroemulsion-based media as novel drug delivery systemsAdv Drug Deliv Rev20004518912111104900
   PubMed Web of Science ®Google Scholar
• MieleESpinelliGPMieleETomaoFTomaoSAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerInt J Nanomedicine200949910519516888
   PubMed Web of Science ®Google Scholar
• StirlandDLNicholsJWMiuraSBaeYHMind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practiceJ Control Release201317231045106424096014
   PubMed Web of Science ®Google Scholar
• JahnMRAndreasenHBFuttererSA comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implicationsEur J Pharm Biopharm201178348049121439379
   PubMed Web of Science ®Google Scholar
• BorchardGFluhmannBMuhlebachSNanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studiesRegul Toxicol Pharmacol201264232432822951348
   PubMed Web of Science ®Google Scholar
• ZagerRAJohnsonACHansonSYWasseHParenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injuryAm J Kidney Dis20024019010312087566
   PubMed Web of Science ®Google Scholar
• YokoyamaMClinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumorsJ Exp Clin Med201134151158
   Google Scholar
• sorrentotherapeutics.com [homepage on the Internet]Cynviloq™ Available from: http://sorrentotherapeutics.com/cynviloq/Accessed November 17, 2013
   Google Scholar
• European Medicines Agency/Committee for Medicinal Products for Human UseJoint MHLW/EMA reflection Paper on the development of Block Copolymer Micelle Medicinal ProductsLondonEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/02/WC500138390.pdfAccessed December 17, 2013
   Google Scholar
• EhmannFSakai-KatoKDuncanRNext-generation nanomedicines and nanosimilars: EU regulators’ initiatives relating to the development and evaluation of nanomedicinesNanomedicine (Lond)20138584985623656268
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyReflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal ProductLondonEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140351.pdfAccessed December 17, 2013
   Google Scholar
• European Medicines AgencyReflection Paper on Non-Clinical Studies for Generic Nanoparticle Iron Medicinal Product ApplicationsLondonEuropean Medicines Agency2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdfAccessed December 17, 2013
   Google Scholar
• European Medicines Agency/Committee for Medicinal Products for Human UseReflection Paper on Nanotechnology-Based Medicinal Products for Human UseLondonEuropean Medicines Agency2006 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069728.pdfAccessed December 17, 2013
   Google Scholar
• KettigerHSchipanskiAWickPHuwylerJEngineered nanomaterial uptake and tissue distribution: from cell to organismInt J Nanomedicine201383255326924023514
   PubMed Web of Science ®Google Scholar
• VamvakasSMartinalboJPitaRIsaacMOn the edge of new technologies (advanced therapies, nanomedicines)Drug Discov Today Technol201181e1e42
   Google Scholar
• MaynardADDon’t define nanomaterialsNature201147573543121734686
   PubMed Web of Science ®Google Scholar
• NystromAMFadeelBSafety assessment of nanomaterials: implications for nanomedicineJ Control Release2012161240340822306428
   PubMed Web of Science ®Google Scholar
• HamburgMAScience and regulation. FDA’s approach to regulation of products of nanotechnologyScience2012336607929930022517845
   PubMed Web of Science ®Google Scholar
• fda.gov [homepage on the Internet]FDA’s approach to regulation of nanotechnology productsSilver Spring, MDUS Food and Drug Administration2012 Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm301114.htmAccessed November 17, 2013
   Google Scholar
• fda.gov [homepage on the Internet]Considering whether an FDA-regulated product involves the application of nanotechnology: guidance for industrySilver Spring, MDUS Food and Drug Administration2011 Available from: http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htmAccessed November 17, 2013
   Google Scholar
• European CommissionVOLUME 2A, Procedures for Marketing Authorization. Chapter 4, centralised procedureLondonEuropean Medicines Agency2006 Available from: http://ec.europa.eu/health/files/eudralex/vol-2/a/chap4rev200604_en.pdfAccessed December 17, 2013
   Google Scholar
• fda.gov [homepage on the Internet]Frequently asked questions about the FDA drug approval processSilver Spring, MDUS Food and Drug Administration2011 Available from: http://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm279676.htmAccessed November 17, 2013
   Google Scholar
• GabellieriCFrimaHNanomedicine in the European Commission policy for nanotechnologyNanomedicine20117551952021802394
   PubMed Web of Science ®Google Scholar
• FrimaHJGabellieriCNilssonMIDrug delivery research in the European Union’s Seventh Framework Programme for ResearchJ Control Release2012161240941522333557
   PubMed Web of Science ®Google Scholar
• GandjourAChernyakNA new prize system for drug innovationHealth Policy20111022–317017721724290
   PubMed Web of Science ®Google Scholar
• PautlerMBrennerSNanomedicine: promises and challenges for the future of public healthInt J Nanomedicine2010580380921042425
   PubMed Web of Science ®Google Scholar
• BCC Research [homepage on the Internet]Nanotechnology in medical applications: the global marketWellesley, MABCC Research LLC2010 Available from: http://www.bccresearch.com/market-research/healthcare/nanotechnology-medical-applications-hlc069a.htmlAccessed August 20, 2013
   Google Scholar
• ETP NanomedicineNANOMEDICINE 2020 Contribution of Nanomedicine to Horizon 2020: white paper to the Horizon 2020 Framework Programme for Research and Innovation – recommendations from the nanomedicine communityETP Nanomedicine2013 Available from: http://www.etp-nanomedicine.eu/public/press-documents/publications/etpn-publications/etpn-white-paper-H2020Accessed December 17, 2013
   Google Scholar
• http://www.etp-nanomedicine.eu.[homepage on the Internet] Available from: http://www.etp-nanomedicine.euAccessed 17 November 2013
   Google Scholar
• GolanOHansenPKaplanGTalOHealth technology prioritization: which criteria for prioritizing new technologies and what are their relative weights?Health Policy20111022–312613521071107
   PubMed Web of Science ®Google Scholar
• Velasco GarridoMGerhardusARottingenJABusseRDeveloping health technology assessment to address health care system needsHealth Policy201094319620219889471
   PubMed Web of Science ®Google Scholar
• KolasaKSchubertSMancaAHermanowskiTA review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policy making processes in PolandHealth Policy20111022–314515121641074
   PubMed Web of Science ®Google Scholar
• OzieranskiPMcKeeMKingLThe politics of health technology assessment in PolandHealth Policy20121082–317819323127957
   PubMed Web of Science ®Google Scholar
• PerlethMBusseRSchwartzFWRegulation of health-related technologies in GermanyHealth Policy199946210512610346284
   PubMed Web of Science ®Google Scholar
• WildCLangerTEmerging health technologies: informing and supporting health policy earlyHealth Policy200887216017118295925
   PubMed Web of Science ®Google Scholar
• MaynardADAitkenRJButzTSafe handling of nanotechnologyNature2006444711726726917108940
   PubMed Web of Science ®Google Scholar
• PepićILovrićJCetina-ČizmekBReichlSFilipović-GrčićJToward the practical implementation of eye-related bioavailability prediction modelsDrug Discov Today2014191314423948143
   PubMed Web of Science ®Google Scholar